Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Health
Biotech
First Opinion
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

Alnylam’s rare disease drug shines in trial, paving way for a brand-new class of medicines

  • Adam Feuerstein

By Adam Feuerstein Sept. 20, 2017

Reprints
John Maraganore
John Maraganore, CEO of Alnylam, hailed the results as validation of a new class of medicines. Keith Bedford/The Boston Globe

The age of RNA interference drugs has arrived.

Alnylam Pharmaceuticals announced positive results Wednesday from a closely watched phase 3 clinical trial of patisiran, the company’s lead drug designed to treat a rare nerve disorder known as familial amyloid polyneuropathy (FAP.)

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

The FDA stands by as the vaping industry flouts…
The FDA stands by as the vaping industry flouts its orders
Long-term study shows most prostate cancer patients don’t need…
Long-term study shows most prostate cancer patients don’t need aggressive treatment
‘Microdosing’ is touted by ’shroomers and Reddit users. Science…
‘Microdosing’ is touted by ’shroomers and Reddit users. Science is starting to test their claims —…
The surprising biomedical legacy of the Iraq War
The surprising biomedical legacy of the Iraq War
Listen: Bancel v. Bernie, Sarepta’s FDA runaround, & Regeneron’s…
Listen: Bancel v. Bernie, Sarepta’s FDA runaround, & Regeneron’s ever-growing blockbuster
FDA advisory panel recommends conditional approval of Biogen’s drug…
FDA advisory panel recommends conditional approval of Biogen’s drug for rare form of ALS

Comments are closed.

Recommended Stories